Literature DB >> 12773172

Role of adapters in Toll-like receptor signalling.

S Akira1, M Yamamoto, K Takeda.   

Abstract

Toll-like receptors (TLRs) play a critical role in the detection of invading pathogens within the body and the subsequent immune response. Individual TLRs recognize distinct microbial components. The TLRs are a type 1 transmembrane receptor that possess an extracellular leucine-rich repeat domain and cytoplasmic domain homologous with that of the interleukin 1 receptor (IL-1R) family. Upon stimulation, TLR recruits the IL-1R-associated kinase (IRAK) via the adapter MyD88, ultimately leading to the activation of nuclear factor-kappaB. Cytokine production in response to all TLR ligands is completely abolished in MyD88-deficient cells, indicating that MyD88 is an essential signalling molecule shared among members of the IL-1R/Toll family. However, several novel adaptor molecules have recently been identified. Evidence is now accumulating showing that differential utilization of these adaptors may activate overlapping as well as distinct signalling pathways, and ultimately give rise to distinct biological effects exerted by individual TLR family members.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12773172     DOI: 10.1042/bst0310637

Source DB:  PubMed          Journal:  Biochem Soc Trans        ISSN: 0300-5127            Impact factor:   5.407


  56 in total

1.  Unexpected similarities in cellular responses to bacterial and viral invasion.

Authors:  Paula M Pitha
Journal:  Proc Natl Acad Sci U S A       Date:  2004-01-12       Impact factor: 11.205

2.  Toll-like receptor ligands directly promote activated CD4+ T cell survival.

Authors:  Andrew E Gelman; Jidong Zhang; Yongwon Choi; Laurence A Turka
Journal:  J Immunol       Date:  2004-05-15       Impact factor: 5.422

Review 3.  The potential for Toll-like receptors to collaborate with other innate immune receptors.

Authors:  Subhankar Mukhopadhyay; Jurgen Herre; Gordon D Brown; Siamon Gordon
Journal:  Immunology       Date:  2004-08       Impact factor: 7.397

Review 4.  TLR4 polymorphisms and disease susceptibility.

Authors:  Mamoona Noreen; Muhammad Ali A Shah; Sheeba Murad Mall; Shazia Choudhary; Tahir Hussain; Iltaf Ahmed; Syed Fazal Jalil; Muhammad Imran Raza
Journal:  Inflamm Res       Date:  2012-01-26       Impact factor: 4.575

5.  Differential ability of surface and endosomal TLRs to induce CD8 T cell responses in vivo.

Authors:  Rajakumar Mandraju; Sean Murray; James Forman; Chandrashekhar Pasare
Journal:  J Immunol       Date:  2014-03-31       Impact factor: 5.422

Review 6.  Kinin B1 receptors: key G-protein-coupled receptors and their role in inflammatory and painful processes.

Authors:  João B Calixto; Rodrigo Medeiros; Elizabeth S Fernandes; Juliano Ferreira; Daniela A Cabrini; Maria M Campos
Journal:  Br J Pharmacol       Date:  2004-11-01       Impact factor: 8.739

7.  Concomitant activation of P2Y(2) and P2Y(6) receptors on monocytes is required for TLR1/2-induced neutrophil migration by regulating IL-8 secretion.

Authors:  Fethia Ben Yebdri; Filip Kukulski; Alain Tremblay; Jean Sévigny
Journal:  Eur J Immunol       Date:  2009-10       Impact factor: 5.532

Review 8.  Association of TLR1, TLR2, TLR4, TLR6, and TIRAP polymorphisms with disease susceptibility.

Authors:  Mamoona Noreen; Muhammad Arshad
Journal:  Immunol Res       Date:  2015-06       Impact factor: 2.829

9.  Specific engagement of TLR4 or TLR3 does not lead to IFN-beta-mediated innate signal amplification and STAT1 phosphorylation in resident murine alveolar macrophages.

Authors:  Antonello Punturieri; Rebecca S Alviani; Timothy Polak; Phil Copper; Joanne Sonstein; Jeffrey L Curtis
Journal:  J Immunol       Date:  2004-07-15       Impact factor: 5.422

10.  TILRR, a novel IL-1RI co-receptor, potentiates MyD88 recruitment to control Ras-dependent amplification of NF-kappaB.

Authors:  Xiao Zhang; Freya Shephard; Hong B Kim; Ian R Palmer; Selina McHarg; Gregory J S Fowler; Luke A J O'Neill; Endre Kiss-Toth; Eva E Qwarnstrom
Journal:  J Biol Chem       Date:  2009-11-25       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.